Aclarion, Inc. income statement ACONW

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Aclarion, Inc. reported revenue of $75,730, up 65.6% from the year before. It recorded a net loss of $7.2 million. The operating loss came to $7.1 million, an operating margin of -9312.5%. Diluted earnings per share were -$13.61. Over the twelve months ended Sep 30, 2026, revenue was $98,560 and the net loss was $10.1 million. Across the 4 fiscal years shown, revenue grew from $60,444 in fiscal 2022 to $75,730 in fiscal 2025, about 7.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022
Revenue	0 +46.1%	0 +65.6%	0 -39.4%	0 +24.8%	0
Cost of revenue	0 -3.9%	0 -18.6%	0 +11.8%	0 +16.0%	0
Gross profit	0 +641.6%	0 +117.5%	-0 -11916.7%	-0 +93.3%	-0
Research and development	1 +22.0%	1 +16.3%	1 +1.8%	1 -18.2%	1
Selling, general and administrative	9 +61.3%	6 +31.4%	5 +14.6%	4 -10.8%	4
Operating expenses	11 +55.4%	7 +29.0%	5 +12.3%	5 -12.3%	6
Operating income	-11 -54.9%	-7 -27.9%	-6 -13.1%	-5 +12.3%	-6
Other non-operating income (expense)	-0 +88.1%	-0 -9598.0%	-0 +91.3%	-0 -207.9%	0
Other income (expense)	1 +211.3%	-0 +87.8%	-1 -4081.3%	-0 +97.7%	-2
Pretax income	-10 -37.9%	-7 -3.4%	-7 -42.4%	-5	—
Income tax	0	0	0	0	0
Net income	-10 -37.9%	-7 -3.4%	-7 -42.4%	-5 +30.5%	-7
Basic EPS	-5.13 +76.1%	-13.61 +99.8%	-7,478.90 +90.6%	-79,782.00 -406743.4%	-19.61
Diluted EPS	-5.13 +76.1%	-13.61 +99.8%	-7,478.90 +90.6%	-79,782.00 -406743.4%	-19.61
Weighted average shares, basic	2 +471.8%	1 +56319.5%	0 +1421.0%	0 -100.0%	0
Weighted average shares, diluted	2 +471.8%	1 +56319.5%	0 +1421.0%	0 -100.0%	0
Other measures
Depreciation and amortization	0 +13.4%	0 +17.7%	0 +18.7%	0 +13.3%	0
EBITDA	-10 -56.2%	-7 -28.3%	-5 -12.9%	-5 +13.0%	-5
Interest coverage	—	—	-86.03x	-44.12x	-3.69x
Margins
Gross margin	29.05%	9.02%	-85.15%	-0.43%	-8.03%
Operating margin	-10,789.22%	-9,312.55%	-12,057.23%	-6,466.48%	-9,201.19%
Pretax margin	-10,260.05%	-9,551.87%	-15,293.78%	-6,513.41%	—
Profit margin	-10,260.05%	-9,551.87%	-15,293.78%	-6,513.41%	-11,694.45%
EBITDA margin	-10,537.94%	-9,012.26%	-11,634.83%	-6,250.74%	-8,963.58%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Services-Medical Laboratories (SIC 8071)
Listed as: ACON (Nasdaq), ACONW (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Broomfield, CO
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1635077
Former names: Nocimed, Inc. (until Oct 26, 2021)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.